BCL2 and B-cell chronic lymphocytic leukemia: The action of ibrutinib is on phosphorylation of BTK and, by extension, inhibition of the BCR signaling pathway while venetoclax targets Bcl-2, one of the most abundant antiapoptotic proteins in CLL lymphocytes.